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Abstract
Novel multifunctional magnetic polycation drug carriers (MPDCs) were
synthesized to provide simultaneous magnetically targeted cancer therapy
and diagnosis via magnetic resonance imaging (MRI). The MPDCs consist of
ultra-sensitive magnetic nanocrystals as MR probes and for magnetic
targeting, and a chemotherapeutic agent encapsulated in
poly(hexadecylcyanoacrylate) (PHDCA) nanoparticles. The PHDCA
nanoparticles were further coated with polycationic polyethylenimine (PEI)
to enhance cellular uptake efficiency. The MPDCs demonstrated
ultra-sensitivity via MRI and sufficient magnetic mobility under an external
magnetic field. Drug loading efficiency and release kinetics were also
investigated. From the cell viability data, the MPDCs were nontoxic and the
doxorubicin hydrochloride (DOX)-loaded MPDCs exhibited excellent
tumorcidal efficacy.
1. Introduction
The application of multifunctional nanocomplexes to the field
of oncology has offered innovative solutions to early cancer
detection, in vivo tumor imaging, personalized diagnostics and
targeted therapeutics [1–4]. Recently, cancer treatment using
polymeric drug carriers has been considered because of their
biodegradability, low cytotoxicity and the ability to control
7 Authors to whom any correspondence should be addressed.
drug release kinetics [5]. Various methods for the delivery
of anti-cancer drugs to specific tumor sites using polymeric
drug carriers have been extensively studied with the aim of
reducing side effects and increasing drug efficacy. Antigen–
antibody interactions, pH, temperature and magnetic field have
been widely used as targeting moieties [6]. Among these,
noninvasive targeted drug delivery to cancer cells, using an
external magnetic field, has been applied to local areas of
various types of cancer [7–9].
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Magnetic nanoparticles can be used as excellent magnetic
resonance imaging (MRI) probes for noninvasive in vivo
monitoring of molecular and cellular events. For example,
we developed ultra-sensitive MR probe systems based on
magnetism-engineered iron oxide nanoparticles. These
considerably enhanced the sensitivity of cancer detection to
enable in vivo imaging of small volume tumors at an early
stage [10]. Furthermore, we recognized that imaging agents
and anti-cancer drugs could be colocalized to specific tumor
sites using polymeric drug carriers through the application of
a noninvasive external magnetic field to allow simultaneous
treatment and diagnosis. This enables us to regulate the amount
of anti-cancer drug injected through real-time monitoring of
tumor volume by MRI. Moreover, simultaneous treatment
and diagnosis will improve the therapeutic outcome of cancer
chemotherapy and result in improved patient compliance
and comfort compared with the two-step cancer treatment
of surgery or chemotherapy followed by detection of tumor
volume change.
In this study, we focused on formulation and character-
ization of multifunctional magnetic polycation drug carriers
(MPDCs) for simultaneous magnetically targeted cancer ther-
apy and diagnosis at the cellular level for a proof of concept, as
in our previous study [11]. The MPDCs contain ultra-sensitive
magnetic nanocrystals as MR probes and for magnetic target-
ing, and doxorubicin hydrochloride (DOX) as an anti-cancer
drug encapsulated in poly(hexadecylcyanoacrylate) (PHDCA)
nanoparticles. As MR and magnetic targeting probes, the
monodispersed magnetic nanocrystals were synthesized in or-
ganic solvent [12]. The PHDCA nanoparticles exhibited rela-
tively rapid degradability in the early stage, which is critical in
magnetically targeted cancer therapy [13]. To achieve stability
in the aqueous phase, magnetic PHDCA nanoparticles (MPNs)
were prepared in a spherical form by stabilizers using the emul-
sion solvent evaporation method. Moreover, cellular uptake
can be increased by cationic polymers such as polyethylen-
imine (PEI), poly(L-lysine), and chitosan, that can easily as-
sociate with negatively charged cell membranes through elec-
trostatic interactions and are internalized into cancer cells by
charge-mediated endocytosis [14–17]. Therefore, the anionic
MPNs were further coated with polycationic PEI to enhance
cellular uptake efficiency through ionic interactions, yielding
PEI/MPNs nanocomplexes (MPDCs) (figure 1). The magnetic
mobility of the MPDCs under an external magnetic field was
observed using epi-fluorescence microscopy. The diagnostic
potential of the MPDCs as magnetic resonance contrast agents
was demonstrated by MRI. Finally, to assess the therapeutic
potential of the MPDCs, we investigated drug release kinet-
ics and cell viability using MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay.
2. Materials and methods
2.1. Materials
Iron(III) acetylacetonate, 1,2-hexadecanediol, dodecanoic
acid, dodecylamine, benzyl ether, hexadecanol, cyanoacetic
acid, 1,4-dimethylaminopyridine, 1,3-dicyclohexylcarbodi-
imide, anhydrous dichloromethane, dimethylamine, polyethyl-
enimine (PEI, Mw: 25k), polyvinyl alcohol (PVA, Mw: 15–
20 kilo.) and rhodamine B were purchased from Sigma-
Aldrich. Doxorubicin hydrochloride (DOX) and fluorescein
Figure 1. Conceptual scheme of multifunctional magnetic
polycation drug carriers (MPDCs). The MPDCs enable drug delivery
to targeted sites using an external magnetic field and can
simultaneously be used as magnetic resonance contrast agents for
local detection. The MPDCs also possess enhanced cellular uptake
efficiency and therapeutic efficacy compared with MPNs due to their
surface characteristics. The outermost polycationic PEI of the
MPDCs allows electrostatic interactions with negatively charged cell
membranes, followed by internalization into cancer cells.
isothiocyanate (FITC) were obtained from Fluka. Phosphate
buffered saline (PBS; 10 mM, pH 7.4) was purchased from
Gibco. All other chemicals and reagents were of analytical
grade.
2.2. Synthesis of magnetic nanocrystals
2 mM of iron (III) acetylacetonate, 10 mM of 1,2-
hexadecanediol, 6 mM of dodecanoic acid, 6 mM of
dodecylamine and benzyl ether (20 ml) were mixed under
ambient nitrogen. The mixture was preheated to 150 ◦C for
30 min and then refluxed at 300 ◦C for 30 min. After cooling to
room temperature, the products were purified with an excess of
pure ethanol. Magnetic nanocrystals of ∼10 nm diameter were
synthesized using the seed-mediated growth method [12].
2.3. Synthesis of HDCA monomers and PHDCA
Hexadecylcyanoacetate (HDCA) monomers were synthesized
by the esterification method [13]. 0.99 g of hexadecanol in
dichloromethane (25 ml) was mixed with 0.38 g of cyanoacetic
acid in ethyl acetate (2.5 ml). The mixture was activated by
addition of 0.11 g of 1,4-dimethylaminopyridine and 0.93 g
of 1,3-dicyclohexylcarbodiimide in dichloromethane (10 ml).
The reaction was carried out for 6 h at room temperature. The
products were added to cold diethyl ether in a dropwise manner
and the precipitates were filtered and lyophilized.
For the synthesis of poly(hexadecylcyanoacrylate)
(PHDCA) by condensation polymerization, 3.1 g of HDCA
monomer was dissolved in ethyl alcohol (30 ml) and
dichloromethane (5 ml) [18]. Then, formaldehyde solution
(37.0%, 0.42 ml) and dimethylamine solution (40.0%, 0.16 ml)
were added to the reactant solution. The reaction was carried
out for 12 h at room temperature. After the solvent was evapo-
rated, the products were washed with diethyl ether before dry-
ing under vacuum. The yield of PHDCA polymer was 91 wt%
(2.82 g).
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2.4. Preparation of MPNs by the emulsion solvent
evaporation method
5 mg of DOX was solubilized in chloroform (5 ml) containing
triethylamine (3–5 M in respect to DOX) by sonication for
10 min [19]. Then, 100 mg of PHDCA polymer and
20 mg of magnetic nanocrystal dissolved in chloroform (5 ml)
were added to the above solution. This organic phase was
added to 1% of PVA (20 ml). After mutual saturation
of the organic and the continuous phase, the mixture was
emulsified for 10 min under ultrasonification (ULH700S,
Ulssohitech) operated at 420 W. After solvent evaporation,
the magnetic PHDCA nanoparticles (MPNs) were purified by
three cycles of centrifugation at 15 000 rpm and stored under
vacuum. To observe the magnetic mobility under magnetic
field using epi-fluorescence microscopy, 0.5 mg rhodamine B
was encapsulated in the MPNs.
2.5. Preparation of multifunctional MPDCs
The multifunctional MPDCs were prepared by ionic self-
assembly of the anionic MPNs and polycationic PEI. 4, 8,
12, 16, 20, 40, 80, 160 and 320 μg PEI dissolved in 1 ml
PBS was added to 8 μg ml−1 solution of MPNs. The mixture
was vortexed for 20 s and gently mixed at 4 ◦C for 15 min
to allow PEI/MPN nanocomplexes (MPDCs). The products
were purified by centrifugation at 5000 rpm, lyophilized and
stored under vacuum. To investigate magnetic mobility of the
MPDCs under external magnetic field using epi-fluorescence
microscopy, 0.5 mg ml−1 of FITC solution was conjugated
with PEI on the surface of MPDCs at room temperature for
12 h. The isothiocyanate group of FITC is exceedingly reactive
towards amine groups of PEI [20].
2.6. Magnetic mobility test of MPDCs
MPDCs stained with fluorescent dyes were injected into a
borosilicate micro-channel (sq I.D. 500 μm, VitroCom Inc.).
The mobility of the MPDCs under a magnetic field (Nd–B–
Fe magnet, 0.35 T) was investigated using an epi-fluorescence
microscope (Olympus, BX51).
2.7. MR imaging
MR imaging experiments were performed with a 1.5 T clinical
MRI instrument with a micro-47 surface coil (Intera, Philips
Medical Systems). T 2 relaxivities (R2) of the MPDCs
containing magnetic nanocrystals were measured at room
temperature by the Carr–Purcell–Meiboom–Gill (CPMG)
sequence: TR = 10 s, 32 echoes with 12 ms even echo space,
number of acquisition = 1, point resolution of 156 μm ×
156 μm, section thickness of 0.6 mm. R2 defined as 1/T 2
with units of s−1. The relaxivity coefficient (mM−1 s−1) equals
the ratio of R2 to the MPDC concentration.
2.8. Drug loading contents, entrapment efficiency and drug
release kinetics
The total amount of drug in the MPDCs suspension was
analysed by drying the sample and dissolving the sample in
5 ml of chloroform. The amount of drug (λmax = 480 nm) in
the oil phase was detected by a UV spectrophotometer (Optizen
2120UV, MECASYS Co.). The drug loading contents and
entrapment efficiency was calculated by using the following
equations:
Drug loading contents (%)
= weight of drug in nanoparticles
weight of prepared nanoparticles
× 100
Entrapment efficiency (%)
= weight of drug in nanoparticles
weight of injected drug × 100.
For the in vitro drug release test, 10 mg of MPDCs
suspended in 1 ml of PBS (10 mM, pH 7.4) was sealed in
a dialysis tube and immersed in 9 ml of PBS at 37 ◦C. The
system was shaken at a moderate speed and the amount of
released drug was monitored using a UV spectrophotometeric
method.
2.9. Affinity test of the MPDCs against the cancer cell line
Human breast adenocarcinoma MDA-MB-231 cells were
obtained from the American Tissue Type Culture (ATCC,
Rockville, MD) and cultured in DMEM/F-12 (1:1) media
supplemented with 10% (v/v) fetal bovine serum (FBS),
100 U ml−1 penicillin, 0.1 mg ml−1 streptomycin and
365 μg ml−1 L-glutamine at 37 ◦C in a 5% CO2-humidified
incubator. All culture media were obtained from Gibco
(Fisher Scientific, Pittsburgh, PA). We used fluorescence-
activated cell sorting (FACS) and MRI to determine the
affinity of the DOX-loaded MPNs (DOX-MPNs) and DOX-
loaded MPDCs (DOX-MPDCs) to the MDA-MB-231 cells.
1 × 106 cells were incubated with DOX-MPNs and DOX-
MPDCs at 37 ◦C for 4 h in the media described above. The
cells were then washed twice with PBS trypsinization and
harvested. The collected cells were washed three times with
0.2% FBS and 0.02% NaN3 in PBS. These samples were
re-suspended in 400 μl of 4% paraformaldehyde, and the
cell-associated fluorescence was determined by FACS-based
analysis of doxorubicin fluorescence using a FACScalibur
(Beckton-Dickinson, Mansfield, MA) with the laser operating
at 488 nm.
2.10. Cytotoxicity studies
Cell viability was determined in MDA-MB-231 cells
maintained in DMEM (Dulbecco’s modified eagle’s medium)
in a 5% CO2 atmosphere. Cytotoxicity of MPNs and MPDCs
was evaluated by measuring the inhibition of cell growth using
MTT assay at various concentrations (4.9–625 μg ml−1). In
addition, MTT assay was conducted with free DOX, DOX-
MPNs and DOX-MPDCs to investigate the cytotoxic efficacy
of DOX-MPDCs. The amount of loading contents of DOX
was 0.35 μg ml−1 as mentioned in section 2.8 (drug loading
contents, entrapment efficiency and drug release kinetics) and
the concentration of DOX was fixed at 0.35 μg ml−1 for
MTT assay. All treatments were performed on cells seeded
in 96-well plates at a cellular density of 4 × 103 cells ml−1.
After treatment, the cells were washed and incubated for an
additional 72 h. MTT assay was performed using the Cell
Proliferation kit (Roche, USA) in triplicate. Cell viabilities
were then finally obtained by the ratio of the number of cells
treated with free DOX, DOX-MPNs, or DOX-MPDCs to the
number of non-treated control cells.
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Figure 2. (a) 1H-NMR spectrum of PHDCA polymers and (b) gel permeation chromatography of (i) PHDCA polymers, (ii) HDCA
monomers.
Figure 3. TEM images of (a) magnetic nanocrystals, (b) MPNs and (c) SEM image of MPNs.
2.11. Statistical analysis
All experiments were performed in triplicate and the values
were expressed as average ± standard deviation. The statistical
evaluation of data was performed by analysis of variance
(ANOVA), followed by Tukey’s test for comparison of relative
T 2 weight value and cell viability from different groups. p <
0.05 was considered to be statistically significant.
2.12. Characterization
The structure of the synthesized PHDCA polymer was
confirmed by 1H-NMR spectra (JNM-ECP300, JEOL Ltd),
and the molecular weight of the PHDCA was measured using
a gel permeation chromatography column (Styragel® HR 2,
Waters). Morphology and size distribution were evaluated with
a transmittance electron microscope (TEM, JEM-1011, JEOL
Ltd) and scanning electron microscope (SEM, JSM-6500F,
JEOL Ltd). Size distribution and surface charge of the MPDCs
were analysed by laser scattering (ELS-Z, Otsuka electronics).
Fourier transform infrared (FT-IR) spectra (Excalibur™ series,
Varian Inc.) analysis was used to confirm the characteristic
bands of the synthesized nanoparticles. The quantity of
magnetic nanocrystals in the MPDCs was determined by a
thermogravimetric analyser (SDT-Q600, TA instrument). The
saturation of magnetization was evaluated using a vibrating-
sample magnetometer (VSM, MODEL-7300, Lakeshore).
Surface composition of the MPDCs was investigated by x-
ray photoelectron spectroscopy (ESCALAB 220i-XL, VG
Scientific Instrument).
3. Results and discussion
Synthesized PHDCA was characterized using a 1H-NMR
spectrometer (figure 2(a)) giving δ values of 4.27 (methylene
in the α-position to the ester groups), 3.64 (methylene protons
of poly(cyanoacrylate)), 1.75 (methylene in the β-position to
the ester groups), 1.26 (methylene of hexadecyl chain) and
0.88 (methyl protons of the hexadecyl chain). The molecular
weight of the PHDCA was 3900 (Mw), with a low index of
polydispersity (1.3) (figure 2(b)).
Using organic solvent, 10.3 ± 0.7 nm of monodisperse
magnetic nanocrystals (Fe3O4) were synthesized (figure 3(a)).
To form the MPNs, magnetic nanocrystals in organic
solvent and DOX were simultaneously encapsulated with the
synthesized PHDCA using the emulsion solvent evaporation
method. Figure 3(b) demonstrates that magnetic nanocrystals
are well incorporated in the PHDCA nanoparticles. The
prepared MPNs have a uniformly spherical shape and
smooth surfaces (figure 3(c)). Furthermore, the narrow size
distribution (105.4 ± 10.0 nm) of the MPNs was confirmed by
laser scattering.
To evaluate the potential for magnetic drug targeting
and the magnetic sensitivity of the MPNs under a magnetic
field, the magnetic moment was analysed using a vibrating
sample magnetometer. The hysteresis loops of pure magnetic
nanocrystals and the MPNs observed at 300 K exhibited
superparamagnetic behavior without magnetic hysteresis
(figure 4). The saturation of magnetization values of the pure
magnetic nanocrystals and the MPNs at 0.9 T were 47.9 and
16.6 emu g−1, respectively. The value for the MPNs was lower
than that of the magnetic nanocrystals due to the presence
4
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Figure 4. Magnetic hysteresis loops using a vibrating sample
magnetometer; (a) magnetic nanocrystals and (b) MPNs.
Figure 5. Thermogravimetric curve of MPNs.
of organic components (PHDCA polymers and DOX). The
amount of magnetic nanocrystals encapsulated in the MPNs
was determined to be 13.4 wt% using a thermogravimetric
analyser (figure 5).
The anionic MPNs were coated with polycationic PEI to
enhance cellular uptake efficiency. As shown in figure 6, the
zeta potential values of the MPDCs increased from −12.2 ±
4.1 mV to 38.0 ± 0.1 mV as the weight ratio of PEI/MPNs
increased. This indicates that there was ionic interaction
between the polycationic PEI and the anionic MPNs at the
surface of the MPNs. MPDCs showed almost the same particle
size and zeta potential values when the ratio of PEI/MPNs
was higher than 10. Therefore, the optimal weight ratio of
PEI/MPNs was determined to be 10.
The presence of the magnetic nanocrystals and PEI
in the MPDCs was confirmed by FT-IR spectra. The
characteristic bands of the PHDCA nanoparticles were
observed at 2277 cm−1 (C≡N) and 1740 cm−1 (O–C=O)
(figure 7(a)). After encapsulating magnetic nanocrystals into
the nanoparticles, a band presented at 550 cm−1 (Fe–O),
depending on the Fe(II) content in the PHDCA (figure 7(b)).
The spectrum of the MPDCs showed characteristic bands at
1600 cm−1 (–NH2) from the primary amine groups of PEI
(figure 7(c)).
Figure 6. Particle size and zeta potential of the MPNs and the
MPDCs according to the PEI/MPNs ratio.
Figure 7. FT-IR spectrum of (a) PHDCA nanoparticles, (b) the
MPNs and (c) the MPDCs.
To further verify the surface modification of the MPDCs,
the surface elemental composition of the MPDCs was
compared with that of the MPNs using x-ray photoelectron
spectroscopy (XPS). The XPS spectra of the MPNs with and
without PEI are illustrated in figure 8. The peaks at 282–
297, 395–410 and 528–548 eV correspond to the elements of
C 1s, N 1s and O 1s, respectively. The relative intensity of the
O 1s peak of the MPNs was lower than that of the MPDCs.
In addition, the Fe 2p peaks of magnetic nanocrystals at 700–
740 eV were not observed in the MPDCs, demonstrating that
the MPDCs had a core–shell structure resulting from ionic
interaction between PEI and the MPNs.
Magnetic mobility under an external magnetic field was
observed as shown in figure 9. The MPDCs well dispersed in
PBS of PCR tube without magnet accumulated on the side of
the tube within 1 min when a magnet was applied (figures 9(a)
and (d)). Epi-fluorescence microscopic images of the MPDCs
stained with fluorescence dye (rhodamine B encapsulated in
the MPDCs and FITC conjugated with PEI) were also obtained
in a rectangular channel of square internal diameter 1.0 mm.
When the commercial Nd–Fe–B magnet (0.35 T) was placed
on the wall of the channel, the MPDCs accumulated on the
wall within 1 min (figures 9(e) and (f)). This demonstrated
5
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Figure 8. XPS analysis of the surface of (a) the MPNs and (b) the
MPDCs.
that the MPDCs had sufficient sensitivity to external magnetic
fields and appeared to have sufficient magnetization to serve as
magnetic drug carriers for targeted delivery.
We also investigated the MR contrasting effect of the
MPDCs by measuring their T 2 relaxivity (R2) to confirm
their utility as MR contrast agents. In the spin–spin relaxation
time (T 2) weighted MR images, the MPDC solution presented
as a dark color at high concentrations (figure 10(a)). The
relaxivity coefficient of the MPDCs (50.2 mM−1 s−1) was
about 1.25 times higher compared to that of the nanocrystals
(40.3 mM−1 s−1) in a previous study (figure 10(b)) [21]. These
results demonstrate that the MPDCs have properties suitable
for magnetic targeted delivery to cancer cells and real-time
monitoring of cancer treatment, despite the presence of the
organic components PHDCA polymers and DOX.
The loading contents and entrapment efficiency of DOX
in the MPDCs were 3.47 and 77.4 wt%, respectively. An in
vitro drug release test was performed in triplicate, and the mean
Figure 10. (a) T 2-weighted MR images of the MPDCs in aqueous
solution. (b) Graph of R2/R2 versus the iron concentration in the
MPDCs.
value and standard deviation were calculated. The in vitro
drug release profile of the MPDCs showed a sustained release
(figure 11). After 10 days, 82% of the encapsulated DOX was
released due to a rapid degradation of PHDCA [22].
The affinity of MPNs and MPDCs to human breast cancer
cells was measured using MDA-MB-231 cells. As shown in
figure 12, the MDA-MB-231 cells incubated with the DOX-
MPDCs demonstrated higher fluorescence intensity by FACS
analysis than those incubated with DOX-MPNs and the relative
intensity was 16.7 times higher than non-treated control cells.
We believe that this enhancement of cell affinity was mainly
contributed by the presence of cationic PEI on the MPDCs.
The changes of T 2-weighted MR signal intensity in cells
indicated the potential of cancer detection (figure 13). In
figure 13, the MR images of MDA-MB-231 cells treated with
Figure 9. Captured images of (a) dispersed MPDCs in PBS after 0 min and (d) accumulated MPDCs on the side of the tube after 1 min with a
magnet. Epi-fluorescence microscopic images of the MPDCs stained with fluorescence dye (rhodamine B encapsulated in the MPDCs and
FITC conjugated with PEI). The images in (b) and (c) show MPDCs with no magnetic field while (e) and (f) show MPDCs accumulated on
the bottom of the channel with a magnetic field. 1000× magnification.
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Figure 11. Drug release profile of MPDCs.
cationic MPDCs exhibited a dark black color (relative T 2
weight, 19.2±2.7%) while the one treated with anionic MPNs
showed gray color (relative T 2 weight, 41.0 ± 2.8%). It
should be remembered that the MPNs treated cells showed
partial enhancement against the MR signal intensity due to
non-specific binding. These noteworthy results indicated that
cationic MPDCs not only exhibited efficient MR imaging
agents but also increased affinity to cancer cells due to
enhancement of electrostatic interaction between cationic
MPDCs and anionic membrane in MDA-MB-231 cells.
We next determined the in vitro cytotoxic activity
measured by MTT assay and the results are shown in figure 14.
In figure 14(a), the cell viability of MPNs and MPDCs
retained over 80% within the concentration range of 4.9–
Figure 13. (a) The T 2-weighted MR images (non-treated; white,
MPNs; gray, MPDCs; black) and (b) graph of relative T 2 weight
values for MDA-MB-231 cells.
156 μg ml−1. To assess the therapeutic efficacy of the
MPDCs, MTT assay was performed with the samples of
free DOX, DOX-MPNs and DOX-MPDCs with various DOX
concentrations (0.001 37–0.35 μg ml−1) based on the initial
DOX concentration (0.35 μg ml−1) in 10 μg ml−1 of DOX-
MPDCs. In figure 14(b), the DOX-MPDCs showed higher
therapeutic efficacy to the DOX-MPNs and free DOX above
0.0055 μg ml−1 of DOX concentration, whereas there is
similar therapeutic efficacy among three types of samples (free
DOX, DOX-MPNs, and DOX-MPDCs) below 0.0055 μg ml−1
of DOX concentration. Moreover, the cytotoxicity of DOX-
MPNs was significantly less compared with that of the DOX-
MPDCs. From the results of cell viability data, the synthesized
MPDCs demonstrated that the cationic MPDCs increased
a
b c
Fluorescence Intensity
Ev
e
n
ts
Figure 12. Flow cytometry results of (a) non-treated control cells, (b) MPNs treated cells and (c) MPDCs treated cells; MDA-MB-231 cells.
(This figure is in colour only in the electronic version)
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Figure 14. The cell viability test of MDA-MB-231 cells by MTT
assay; treated with (a) MPNs and MPDCs at various concentrations
of particles, (b) free DOX, DOX-MPNs and DOX-MPDCs at various
concentrations of DOX.
the cell affinity with anionic membrane of cancer cells and
enhanced uptake into intracellular cytoplasm in parallel with
excellent therapeutic efficacy.
4. Conclusion
We successfully synthesized novel MPDCs composed of
magnetic nanocrystals and anti-cancer drug encapsulated in
PHDCA nanoparticles covered with a PEI layer. The
MPDCs demonstrated sufficient magnetic mobility under
external magnetic field and ultrasensitivity for simultaneous
magnetically targeted drug carriers using MR probes for the
detection of cancer. Furthermore, the cationic surface of
the MPDCs enhanced the efficiency of cellular uptake by
cancer cells. Moreover, the MTT assay results proved that
the synthesized MPDCs were nontoxic and the DOX-MPDCs
exhibited excellent tumorcidal efficacy. These multifunctional
MPDCs can be applied to magnetically targeted drug carriers
which also facilitate simultaneous diagnosis by MRI. Further
in vivo studies are in progress.
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